News | Mammography | August 26, 2016

Hologic's C-View Software Similar to Genius 3-D Mammography in Clinical Performance

Low Dose 3-D Mammography exams maintain invasive cancer detection rates, reduce unnecessary patient recalls with lower dose

Hologic, C-View software, 3-D Mammography, clinical performance study

August 26, 2016 — Hologic Inc. announced that a recent study shows Low Dose 3-D Mammography exams with C-View software are comparable to traditional Genius 3-D Mammography exams. The study, conducted by University of Pennsylvania researchers and published online in advance of print by Radiology, showed similar overall and invasive breast cancer detection, as well as recall rates.

Hologic’s C-View software was created for physicians and patients seeking a low-dose screening option with the same clinical benefits as the Genius exam. With C-View software, a 2-D image is generated using the tomosynthesis data acquired during the mammography exam, eliminating the need for additional 2-D exposures. As a result, the radiation dose is lowered to one similar to conventional mammography alone, and the exam’s compression time is reduced. 

This is the first major U.S. study that compares the performance of Low Dose 3-D Mammography exams to traditional Genius exams. Lancet Oncology previously published findings of a European study with similar conclusions.

The study, led by Emily Conant, M.D., from the Breast Imaging Division, Department of Radiology, Hospital of the University of Pennsylvania, compared recall rates, biopsy rates, cancer detection rates and radiation dose for 15,571 women who received a traditional Genius exam (digital mammography/digital breast tomosynthesis [DBT]) and 5,366 women who were screened with Hologic’s Low Dose 3-D Mammography exam (synthesized 2-D/DBT). Both screening methods had comparable performance, but the associated dose was significantly reduced by 39 percent with the adoption of C-View software. Furthermore, the low-dose screening option demonstrated an increase in the probability of a patient’s biopsy finding cancer, in comparison to traditional Genius exams.

“In our study, the replacement of standard 2-D mammography with C-View 2-D images in combination with a tomosynthesis exam resulted in equivalent cancer detection,” said Conant, senior author of the study. “Additionally, using synthetic 2-D images resulted in a significant reduction in radiation dose while maintaining the reduction in recalls from screening.”

This study was conducted on Hologic’s Selenia Dimensions mammography system using the company’s C-View software and as such, the results are not applicable to other manufacturers’ technology.

Hologic’s Low Dose 3-D Mammography exam with C-View software is CE-marked, U.S. Food and Drug Administration (FDA)-approved and is commercially available in the United States and Europe. The Genius 3-D Mammography exam is only available on the Hologic Selenia Dimensions system.

For more information: www.pubs.rsna.org/journal/radiology

Related Content

Novel Technique May Significantly Reduce Breast Biopsies
News | Breast Biopsy Systems | January 17, 2019
A novel technique that uses mammography to determine the biological tissue composition of a tumor could help reduce...
Digital Mammography Increases Breast Cancer Detection
News | Mammography | January 16, 2019
The shift from film to digital mammography increased the detection of breast cancer by 14 percent overall in the United...
Artificial Intelligence Used in Clinical Practice to Measure Breast Density
News | Artificial Intelligence | January 15, 2019
An artificial intelligence (AI) algorithm measures breast density at the level of an experienced mammographer,...
Sponsored Content | Videos | Breast Imaging | January 11, 2019
Supplemental screening with ABUS helps personalize breast care for women with dense breasts and offers advanced...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a...
Opto-Acoustic Imaging Helps Differentiate Breast Cancer Molecular Subtypes
News | Ultrasound Women's Health | December 20, 2018
Seno Medical Instruments Inc. (Seno Medical) reported results of a study demonstrating that morphologic and functional...
Densitas Enters Platform Partnership With Blackford
News | Breast Density | December 19, 2018
Breast imaging analytics company Densitas Inc. announced the signing of a new Alliance Partner Agreement with Blackford...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RSNA Study Shows Real-Time Indicator Improves Mammographic Compression
News | Mammography | December 12, 2018
Sigmascreening recently announced that more than 100,000 women have had mammography exams with the Sensitive Sigma...